Xenon Pharmaceuticals Inc (XENE)

$39.24 1.08 (2.67%)

14:52 EDT XENE Stock Quote Delayed 30 Minutes

3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition

By Gabriel Osorio-Mazzilli, InvestorPlace Contributor Feb 21, 2024

Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.

Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Xenon Pharmaceuticals Has a Great Story But Too High a Price

More Articles

Volume:

Previous Close -

Market Cap 2.49B

PE Ratio -62.28

EPS -0.63

Volume (Avg. Vol.) 194,474

Day's Range $39.01 - $41.26

52-Week Range $27.99 - $50.99

Dividend & Yield N/A (N/A)

XENE Stock Predictions, Articles, and Xenon Pharmaceuticals Inc News

From InvestorPlace
From the Web

Xenon: Heading Toward Phase III With Strong Momentum

By Ian Bezek, InvestorPlace Contributor Oct 26, 2021

Xenon just delivered strong clinical trial results and leveraged that into a strong fundraising effort. That has XENE stock in a good place going forward.

New Clinical Results Make Xenon Pharmaceuticals’ Stock Worthy Again

By Louis Navellier and the InvestorPlace Research Staff Oct 19, 2021

XENE stock deserved to move higher but was stuck for months -- until a game-changing epilepsy treatment put Xenon in the spotlight again.

XENE Stock: The Huge FDA News Sending Xenon Pharmaceuticals to the Moon

By Chris MacDonald, InvestorPlace Contributor Oct 4, 2021

Here's why investors in clinical-stage biotech stock Xenon Pharmaceuticals are cheering today as XENE stock runs wild.

Xenon Pharmaceuticals Inc (XENE) Plunges on Acne Drug Flop

By William White, InvestorPlace Writer Mar 24, 2017

Xenon Pharmaceuticals (XENE) stock was falling hard on Friday following results from a recent study of its acne drug XEN801.

Notable earnings after Thursday's close

From Seeking Alpha Feb 28, 2024

Major earnings expected after the bell on Thursday include:Zscaler (ZS)Hewlett Packard Enterprise Company (HPE)Dell Technologies (DELL)Autodesk (ADSK)Veeva...

Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

From MarketBeat Dec 29, 2023

Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.

Xenon Pharmaceuticals announces proposed public offering (NASDAQ:XENE)

From Seeking Alpha Nov 29, 2023

Xenon Pharmaceuticals announces a proposed underwritten public offering of $225.0M of its common shares, with an option for additional shares.

Xenon mid-stage trial for depression fails (NASDAQ:XENE)

From Seeking Alpha Nov 27, 2023

Xenon Pharmaceuticals (XENE) says its depression candidate XEN1101 fell short in Phase 2 trial, but certain measures showed early efficacy. Read more here.

Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Xenon (XENE) and Alcon (ALC)

From TipRanks Nov 19, 2022

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Catalent (

Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Xenon (XENE)

From TipRanks Nov 11, 2022

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medtronic (

ADVERTISEMENT